One obesity readout carries the story
- GPCR has no approved products and has not generated product revenue.
- Its lead drug, aleniglipron, is an oral GLP-1 receptor agonist for obesity and being overweight.
- The main catalyst is topline data from the ACCESS and ACCESS II Phase 2b obesity studies, expected in Q4 2025.
- Cash, cash equivalents, and short-term investments were $836.9M as of March 31, 2025.
- R&D expense rose 107% year over year to $42.9M in the March 2025 quarter.
- Supply risk is real because key drug materials come from WuXi STA, a subsidiary of WuXi AppTec.
A big bet on oral obesity drugs
Structure Therapeutics is a clinical-stage biotech. That means the company is still trying to prove its drugs work and are safe. It has not sold an approved product yet.
The bull case is simple. If aleniglipron shows strong 36-week weight loss and clean safety in the ACCESS and ACCESS II studies, GPCR could have a valuable oral GLP-1 drug in a huge obesity market. Pills could be easier for many patients than injections.
The bear case is also simple. The obesity market is crowded, and large drug companies already have approved GLP-1 products. GPCR also spent much more on R&D in the March 2025 quarter, so the cost of being wrong is rising.
The next major test is Q4 2025. That is when the company expects topline data from both Phase 2b obesity studies. The same period also includes supply chain uncertainty tied to WuXi AppTec and any new action on the BIOSECURE Act.
No sales yet, equity funds the trials
GPCR does not make money from drug sales today. Its model is to discover and develop small molecule drugs, run clinical trials, seek regulatory approval, and then sell the drug itself or partner with a larger drug company.
The company funds this work with money raised from investors. As of March 31, 2025, it had $836.9M in cash, cash equivalents, and short-term investments. Management says that should fund planned work through at least 2027, including aleniglipron studies needed for Phase 3 readiness, but excluding Phase 3 registration trials.
The main cost is research and development. R&D expense was $42.9M in the first quarter of 2025, up 107% from $20.7M in the first quarter of 2024. That jump shows the trials are moving, but it also means the company will likely need much more capital if it reaches Phase 3.
GPCR keeps a lean setup by using outside manufacturers. The weak point is that key drug materials currently come from WuXi STA, a subsidiary of WuXi AppTec. GPCR is working on suppliers outside China, but that shift is not finished.
Pipeline led by aleniglipron
Aleniglipron, GSBR-1290
This is the lead oral GLP-1 receptor agonist for obesity and being overweight. Enrollment in ACCESS and ACCESS II was completed in February 2025, with topline data expected in Q4 2025.
LTSE-2578
This is an oral LPA1 receptor antagonist for idiopathic pulmonary fibrosis, a serious lung disease. It started a Phase 1 trial in June 2024, with initial data expected in 2025.
ANPA-0073
This candidate is aimed at selective weight loss. It is Phase 2 ready, but still depends on long-term toxicology studies before moving further.
ACCG-2671
This is an oral small molecule amylin receptor agonist for obesity. The company expects to start a Phase 1 study in Q4 2025.
Discovery and preclinical programs
These are earlier drug ideas from the company’s structure-based discovery platform. They may add value later, but they are not the near-term driver.
One pre-revenue R&D business
GPCR reported as a single business focused on research and development, with no product revenue. The mix below reflects the economic reality as of the latest filed period, not sales by product line.
What could go wrong
ACCESS data disappoints
High impact · Medium oddsAleniglipron is the core value driver. If the Q4 2025 Phase 2b data show weak weight loss, safety problems, or too many patients stopping treatment, the stock story could break fast.
Oral GLP-1 competition wins first
High impact · High oddsThe obesity market already has major approved GLP-1 drugs, and more oral small molecules are in development. Even a working GPCR drug must look good enough on weight loss, side effects, dosing, and price.
Cash burn keeps rising
Medium impact · High oddsGPCR had an accumulated deficit of $375.9M as of March 31, 2025. R&D expense more than doubled year over year in the March 2025 quarter. The current cash runway reaches at least 2027 under the company’s plan, but Phase 3 trials are excluded from that runway statement.
WuXi supply chain disruption
High impact · Medium oddsGPCR relies on WuXi STA, a subsidiary of WuXi AppTec, for active pharmaceutical ingredients and drug product. The company is pursuing suppliers outside China, but a forced or rushed change could affect timing, cost, or quality.
Regulatory path proves harder than planned
High impact · Medium oddsGPCR has no approved products and no experience submitting a new drug application. Later-stage obesity trials can be large, expensive, and strict on safety because patients may take the drug for a long time.
In one breath
What does Structure Therapeutics do?
Structure Therapeutics develops oral small molecule drugs for chronic diseases. Its lead program is aleniglipron, an oral GLP-1 receptor agonist for obesity and being overweight.
Does GPCR have revenue?
No. GPCR has not generated product revenue because none of its drug candidates are approved for sale.
What is the biggest upcoming GPCR catalyst?
The main catalyst is topline data from the ACCESS and ACCESS II Phase 2b obesity studies. The company expects those data in Q4 2025.
Why does the BIOSECURE Act matter for GPCR?
GPCR uses WuXi STA, a subsidiary of WuXi AppTec, for key drug supplies. If U.S. law restricts work with certain China-linked biotech suppliers, GPCR may need to shift manufacturing faster than planned.